To the Editor We read with interest a Research Letter published in a recent issue of JAMA Internal Medicine by Hartung et al.1 Mallinckrodt, manufacturer of repository corticotropin injection (H.P. Acthar Gel [Acthar]), is dedicated to providing appropriate treatment options for patients with inflammatory and autoimmune diseases, and we would like to share our view on Acthar.2
Otulana T. Uses of H.P. Acthar Gel in the Clinical Setting. JAMA Intern Med. 2018;178(4):583. doi:10.1001/jamainternmed.2017.8542
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.